Notwithstanding different setbacks, many MDM2 inhibitors have now progressed into late-phase clinical improvement. New methods have also been produced to reinforce the efficacy of MDM2 inhibitors also to mitigate their on-target toxicity. In this overview, we summarize the development and challenges in the event of a MDM2 qualified therapy.BACKGROU